L Maitrot-Mantelet1, M H Horellou2, H Massiou3, J Conard2, A Gompel1, G Plu-Bureau4. 1. Unit of Gynecological Endocrinology, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, France. 2. Unit of Hemostasis, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, France. 3. Unit of Neurology, Lariboisière Hospital, AP-HP, France. 4. Unit of Gynecological Endocrinology, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, France; Unit of Hemostasis, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, France; Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease, Villejuif, France. Electronic address: genevieve.plu-bureau@cch.aphp.fr.
Abstract
INTRODUCTION: Migraine, particularly migraine with aura (MA), is associated with a higher risk for ischemic stroke (IS). A procoagulant state may predispose to IS. Whether inherited biological thrombophilia are associated with migraine risk remains controversial. OBJECTIVE: To assess the risk of migraine without or with aura related to inherited biological thrombophilia adjusted for the main potential confounders. MATERIAL AND METHODS: A cross-sectional study was conducted in 1456 French women aged 18 to 56years, referred for biological coagulation check-up because of personal or familial venous thrombosis history. Between April 2007 and December 2008, all women answered a self-administered questionnaire to determine whether they had headache. RESULTS: There were 294 (20%) migrainous sufferers (including 71 [5%] with MA), 975 (67%) non migrainous women and 187 (13%) non migrainous headache women. Inherited thrombophilia were detected in 576 (40%) women, including 389 (40%) non migrainous women, 90 (40%) migraine without aura (MWA), 33 (46%) MA women and 64 (34%) non migrainous headache women. Factor V Leiden (FVL) i.e. F5rs6025 or Factor II G20210A (FIIL) i.e. F2rs1799963 mutation was detected in 296 (30%) non migrainous women and in 100 (34%) migrainous women of which 27 had MA. There was a significant association between MA and FVL or FIIL mutations (adjusted OR=1.76 [95% CI 1.02-3.06] p=0.04) whereas this association in MWA and in non migrainous headache women was not significant. There was no significant association between migraine and other biological thrombophilia. CONCLUSION: FVL or FIIL mutations were more likely among patients suffering from MA. Whether biological thrombophilia screening should be systematically performed in women suffering from MA remains to be determined.
INTRODUCTION:Migraine, particularly migraine with aura (MA), is associated with a higher risk for ischemic stroke (IS). A procoagulant state may predispose to IS. Whether inherited biological thrombophilia are associated with migraine risk remains controversial. OBJECTIVE: To assess the risk of migraine without or with aura related to inherited biological thrombophilia adjusted for the main potential confounders. MATERIAL AND METHODS: A cross-sectional study was conducted in 1456 French women aged 18 to 56years, referred for biological coagulation check-up because of personal or familial venous thrombosis history. Between April 2007 and December 2008, all women answered a self-administered questionnaire to determine whether they had headache. RESULTS: There were 294 (20%) migrainous sufferers (including 71 [5%] with MA), 975 (67%) non migrainouswomen and 187 (13%) non migrainous headachewomen. Inherited thrombophilia were detected in 576 (40%) women, including 389 (40%) non migrainouswomen, 90 (40%) migraine without aura (MWA), 33 (46%) MA women and 64 (34%) non migrainous headachewomen. Factor V Leiden (FVL) i.e. F5rs6025 or Factor II G20210A (FIIL) i.e. F2rs1799963 mutation was detected in 296 (30%) non migrainouswomen and in 100 (34%) migrainouswomen of which 27 had MA. There was a significant association between MA and FVL or FIIL mutations (adjusted OR=1.76 [95% CI 1.02-3.06] p=0.04) whereas this association in MWA and in non migrainous headachewomen was not significant. There was no significant association between migraine and other biological thrombophilia. CONCLUSION:FVL or FIIL mutations were more likely among patients suffering from MA. Whether biological thrombophilia screening should be systematically performed in women suffering from MA remains to be determined.